Cure Today

Alternative Docetaxel Dosing Reduces Toxicity Risk in Prostate Cancer

The ARASAFE study showed that a 50 mg/m2 biweekly docetaxel regimen reduced severe side effects compared to the standard 75 mg/m2 triweekly regimen in mHSPC patients. The experimental regimen resulted ...
ascopubs.org

Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial

In total, 61 patients with 67 events in the EC-D arm and 76 patients with 79 events in the DC arm. Including patients with recurrence after breast cancer but unknown cause of death. Fig 1. Cumulative ...
ascopubs.org

First-Line Docetaxel Once Every 2 Weeks With Cisplatin Plus Fluorouracil for Metastatic Esophageal Cancer: A Multicenter, Randomized Controlled Phase III Study (JCOG1314, MIRACLE)

Response to Biologics in Patients With Early-Onset Treatment-Naïve Metastatic Colorectal Cancer—An Aide et Recherche en Cancérologie Digestive Database Analysis Overall, 240 patients were randomly ...
Reuters

Taxotere improves survival in head-neck cancer

BOSTON, Oct 24 (Reuters) - Adding the Sanofi-Aventis cancer drug Taxotere to standard chemotherapy helps people with head and neck cancer live more than three years longer, two teams of researchers ...
BioWorld

OV-329 boosts docetaxel effects in TNBC models

Researchers from Ovid Therapeutics Inc. presented preclinical efficacy data on the combination of OV-329, a small-molecule inhibitor of the mitochondrial GABA aminotransferase (GABA-AT) enzyme, with ...